
RGLS
Regulus Therapeutics Inc
- Overview
- Forecast
- Valuation

Line
|

Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
7.880
Open
7.830
VWAP
7.84
Vol
1.42M
Mkt Cap
543.15M
Low
7.810
Amount
11.10M
EV/EBITDA(TTM)
--
Total Shares
65.47M
EV
467.37M
EV/OCF(TTM)
--
P/S(TTM)
--
Regulus Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing drugs targeting microRNAs to treat diseases. The Company is leveraging its oligonucleotide drug discovery and development to develop a pipeline complemented by a rich intellectual property estate in the microRNA field. The Company’s lead product candidate includes RGLS8429. The Company is developing single-stranded oligonucleotides, which are chemically synthesized chains of nucleotides that are complementary to (thereby pairing with) the target microRNA. RGLS8429 is an anti-miR next-generation oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease (ADPKD). RGLS8429 maintains beneficial attributes, such as preferential kidney exposure and similar PK profile, miR-17 inhibition potency and duration of action in the kidney, equal potency in vitro and in vivo efficacy studies.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q3
FY2025Q2
FY2025Q1
--
--
-0.310
+47.62%
--
--
-0.310
+82.35%
--
--
-0.265
-8.62%
Estimates Revision
The market is revising No Change the revenue expectations for Regulus Therapeutics Inc. (RGLS) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 518.11%.
EPS Estimates for FY2025
Revise Downward

-11.91%
In Past 3 Month
Stock Price
Go Up

+518.11%
In Past 3 Month
5 Analyst Rating

62.42% Upside
Wall Street analysts forecast RGLS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RGLS is 12.75 USD with a low forecast of 6.00 USD and a high forecast of 28.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Buy
0 Hold
0 Sell
Strong Buy

62.42% Upside
Current: 7.850

Low
6.00
Averages
12.75
High
28.00

62.42% Upside
Current: 7.850

Low
6.00
Averages
12.75
High
28.00
Wells Fargo
Yanan Zhu
Buy
to
Hold
Downgrades
$9
2025-05-01
New
Reason
Wells Fargo
Yanan Zhu
Price Target
$9
2025-05-01
New
Downgrades
Buy
to
Hold
Reason
Wells Fargo downgraded Regulus (RGLS) to Equal Weight from Overweight with a price target of $9, up from $6, after the company agreed to be acquired by Novartis (NVS) for $7 per share in cash and a $7 per share contingent value right.
Canaccord Genuity
Whitney Ijem
Strong Buy
to
Hold
Downgrades
$28 → $11
2025-04-30
Reason
Canaccord Genuity
Whitney Ijem
Price Target
$28 → $11
2025-04-30
Downgrades
Strong Buy
to
Hold
Reason
Canaccord downgraded Regulus (RGLS) to Hold from Buy with a price target of $11, down from $28, after the company agreed to be acquired by Novartis (NVS) for $7 per share in cash and a $7 per share contingent value right.
Jones Trading
Catherine Novack
Strong Buy
to
Hold
Downgrades
$8 → $7
2025-04-30
Reason
Jones Trading
Catherine Novack
Price Target
$8 → $7
2025-04-30
Downgrades
Strong Buy
to
Hold
Reason
JonesResearch analyst Catherine Novack downgraded Regulus (RGLS) to Hold from Buy with a price target of $7, down from $8, after the company agreed to be acquired by Novartis (NVS) for $7 per share in cash and a $7 per share contingent value right. The firm sees the valuation of the deal as "highly favorable" for Regulus, especially given financing overhang ahead of the Phase 3 trial.
Leerink Partners
Joseph Schwartz
Buy
to
Hold
Downgrades
$7
2025-04-30
Reason
Leerink Partners
Joseph Schwartz
Price Target
$7
2025-04-30
Downgrades
Buy
to
Hold
Reason
Leerink downgraded Regulus (RGLS) to Market Perform from Outperform with a $7 price target after the company agreed to be acquired by Novartis (NVS) for $7 per share in cash and a $7 per share contingent value right.
Wells Fargo
Yanan Zhu
Hold
to
Buy
Upgrades
$3 → $6
2025-03-27
Reason
Wells Fargo
Yanan Zhu
Price Target
$3 → $6
2025-03-27
Upgrades
Hold
to
Buy
Reason
Wells Fargo upgraded Regulus to Overweight from Equal Weight with a price target of $6, up from $3.
Canaccord Genuity
Whitney Ijem
Strong Buy
Maintains
$28
2025-03-17
Reason
Canaccord Genuity
Whitney Ijem
Price Target
$28
2025-03-17
Maintains
Strong Buy
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for Regulus Therapeutics Inc (RGLS.O) is -5.98, compared to its 5-year average forward P/E of -1.74. For a more detailed relative valuation and DCF analysis to assess Regulus Therapeutics Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A
5Y Average PE
-1.74
Current PE
-5.98
Overvalued PE
-0.69
Undervalued PE
-2.80
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A
5Y Average EV/EBITDA
-0.08
Current EV/EBITDA
-6.93
Overvalued EV/EBITDA
0.71
Undervalued EV/EBITDA
-0.88
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A
5Y Average PS
598.34
Current PS
0.00
Overvalued PS
2251.68
Undervalued PS
-1055.00
Financials
Annual
Quarterly
FY2024Q4
N/A
Total Revenue
FY2024Q4
YoY :
+65.61%
-13.75M
Operating Profit
FY2024Q4
YoY :
+58.68%
-12.79M
Net Income after Tax
FY2024Q4
YoY :
-50.00%
-0.20
EPS - Diluted
FY2024Q4
YoY :
+91.17%
-11.85M
Free Cash Flow
FY2024Q4
N/A
Gross Profit Margin - %
FY2024Q4
N/A
FCF Margin - %
FY2024Q4
N/A
Net Margin - %
Trading Trends
Insider
Insiders areBuying! The selling amount has increased 930.87% over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
310.7K
USD
7
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
2
75.0K
USD
Months
6-9
0
0.0
USD
Months
0-12
1
7.3K
USD
Months
Hedge Fund
Hedge Funds areSelling! The selling amount has increased 5274.88% over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
430.0K
Volume
1
6-9
Months
0.0
Volume
0
0-12
Months
8.0K
Volume
2
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders areBuying! The selling amount has increased 930.87% over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
310.7K
USD
7
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
2
75.0K
USD
Months
6-9
0
0.0
USD
Months
0-12
1
7.3K
USD
Months
RGLS News & Events
Events Timeline
2025-05-01 (ET)
2025-05-01
08:45:01
Largest borrow rate increases among liquid names

2025-04-30 (ET)
2025-04-30
07:04:32
Regulus to be acquired by Novartis for $7.00 per share in cash

2025-03-27 (ET)
2025-03-27
07:04:17
Regulus' farabursen shows efficacy in Phase 1b kidney disease trial

Sign Up For More Events
Sign Up For More Events
News
4.0
05-01BenzingaThis Parsons Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Thursday
7.0
05-01PRnewswireSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RGLS, KRON, SWTX on Behalf of Shareholders
8.5
05-01SeekingAlphaRegulus CVR may be worth $3-$4 a share in Novartis deal - analyst
Sign Up For More News
People Also Watch

MBAV
M3-Brigade Acquisition V Corp
10.365
USD
+0.14%

NL
NL Industries Inc
8.670
USD
-2.47%

QUAD
Quad/Graphics Inc
5.490
USD
+4.97%

ENGN
enGene Holdings Inc
3.680
USD
-3.66%

ALF
Centurion Acquisition Corp
10.370
USD
+0.29%

EWCZ
European Wax Center Inc
3.180
USD
-5.36%

SB
Safe Bulkers Inc
3.500
USD
+1.45%

CRD.A
Crawford & Co
11.150
USD
0.00%

BKSY
Blacksky Technology Inc
8.620
USD
-2.49%

RGNX
Regenxbio Inc
9.760
USD
-6.15%
FAQ

What is Regulus Therapeutics Inc (RGLS) stock price today?
The current price of RGLS is 7.85 USD — it has increased 0 % in the last trading day.

What is Regulus Therapeutics Inc (RGLS)'s business?

What is the price predicton of RGLS Stock?

What is Regulus Therapeutics Inc (RGLS)'s revenue for the last quarter?

What is Regulus Therapeutics Inc (RGLS)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Regulus Therapeutics Inc (RGLS)'s fundamentals?

How many employees does Regulus Therapeutics Inc (RGLS). have?
